{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T16:19:31Z","timestamp":1782922771704,"version":"3.54.5"},"reference-count":27,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T00:00:00Z","timestamp":1627689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["IO1 BX003667"],"award-info":[{"award-number":["IO1 BX003667"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["205320_16935"],"award-info":[{"award-number":["205320_16935"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005708","name":"EMC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005708","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:label\/>\n                  <jats:p>Amphotericin B (AmB) is used to treat cryptococcal meningoencephalitis. However, the mortality rate remains high. Higher doses of AmB in deoxycholate buffer (AmBd) are toxic to human red blood cells (hRBC) and have no effect on brain organism load in mice. Here we show that while AmBd lysed 96% of hRBC, AmB complexed with gold nanoparticles (AuNP-SA-AmB) lysed only 27% of hRBC. In vitro growth of C. neoformans was inhibited by 0.25\u00a0\u03bcg\/ml AmBd and 0.04\u00a0\u03bcg\/ml of AuNP-SA-AmB. In mice infected with C. neoformans, five daily treatments with AuNP-SA-AmB containing 0.25\u00a0mg\/kg AmB significantly lowered the fungal burden in the brain tissue compared to either untreated or treatment with 0.25\u00a0mg\/kg of AmBd. When a single dose of AmBd was injected intravenously into BALB\/c mice, 81.61% of AmB cleared in the \u03b1-phase and 18.39% cleared in the \u03b2-phase at a rate of 0.34% per hour. In contrast, when AuNP-SA-AmB was injected, 49.19% of AmB cleared in the \u03b1-phase and 50.81% of AmB cleared in the \u03b2-phase at a rate of 0.27% per hour. These results suggest that AmB complexed with gold nanoparticles is less toxic to hRBC, is more effective against C. neoformans and persists longer in blood when injected into mice resulting in more effective clearing of C. neoformans from the brain tissue.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Lay summary<\/jats:title>\n                  <jats:p>Amphotericin B (AmB) was complexed with gold nanoparticles (AuNP-SA-AmB) to improve brain delivery. AuNP-SA-AmB was more effective than AmB alone in clearing of Cryptococcus neoformans from the brain tissue of infected mice. This may be due to longer plasma half-life of AmB as AuNP-SA-AmB.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/mmy\/myab042","type":"journal-article","created":{"date-parts":[[2021,7,31]],"date-time":"2021-07-31T23:12:09Z","timestamp":1627773129000},"page":"1085-1091","source":"Crossref","is-referenced-by-count":14,"title":["Complexing amphotericin B with gold nanoparticles improves fungal clearance from the brains of mice infected with Cryptococcal neoformans"],"prefix":"10.1093","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1838-2687","authenticated-orcid":false,"given":"Koteswara R","family":"Chintalacharuvu","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, VA Greater Los Angeles Health Care System, Los Angeles, CA 90073, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zlatko A","family":"Matolek","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, VA Greater Los Angeles Health Care System, Los Angeles, CA 90073, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benny","family":"Pacheco","sequence":"additional","affiliation":[{"name":"Cytodiagnostics Inc., 919 Fraser Dr. Unit 11, Burlington, ON L7L 4\u00d78, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erick M","family":"Carriera","sequence":"additional","affiliation":[{"name":"ETH-Z\u00fcrich, Department of Chemistry and Applied Biosciences, Laboratory of Organic Chemistry, Vladimir Prelog Weg 3, HCI H335, Z\u00fcrich 8093, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David O","family":"Beenhouwer","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, VA Greater Los Angeles Health Care System, Los Angeles, CA 90073, USA"},{"name":"Department of Medicine, Geffen School of Medicine at UCLA, Los Angeles, CA 90025, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,7,31]]},"reference":[{"key":"2021110223543013600_bib1","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1086\/649858","article-title":"Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America","volume":"50","author":"Perfect","year":"2010","journal-title":"Clin Infect Dis."},{"key":"2021110223543013600_bib2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/jac\/28.suppl_B.63","article-title":"Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome)","volume":"28","author":"Adler-Moore","year":"1991","journal-title":"J Antimicrob Chemother."},{"key":"2021110223543013600_bib3","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/588792","article-title":"High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: a randomized trial","volume":"47","author":"Bicanic","year":"2008","journal-title":"Clin Infect Dis."},{"key":"2021110223543013600_bib4","doi-asserted-by":"crossref","first-page":"71","DOI":"10.4103\/0022-3859.65276","article-title":"Liposomal amphotericin B (Fungisome) for the treatment of cryptococcal meningitis in HIV\/AIDS patients in India: a multicentric, randomized controlled trial","volume":"56","author":"Jadhav","year":"2010","journal-title":"J Postgrad Med."},{"key":"2021110223543013600_bib5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: side effects and toxicity","volume":"26","author":"Laniado-Laborin","year":"2009","journal-title":"Rev Iberoam Micol."},{"key":"2021110223543013600_bib6","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1128\/AAC.42.4.899","article-title":"Comparison of fungizone, Amphotec, AmBisome, and Abelcet for treatment of systemic murine cryptococcosis","volume":"42","author":"Clemons","year":"1998","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223543013600_bib7","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/17425255.3.4.573","article-title":"CNS pharmacokinetics of antifungal agents","volume":"3","author":"Kethireddy","year":"2007","journal-title":"Expert Opin Drug Metab Toxicol."},{"key":"2021110223543013600_bib8","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","article-title":"Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion","volume":"57","author":"Vogelsinger","year":"2006","journal-title":"J Antimicrob Chemother."},{"key":"2021110223543013600_bib9","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/0731-7085(95)01566-4","article-title":"Determination of amphotericin B in cerebrospinal fluid by solid-phase extraction and liquid chromatography","volume":"13","author":"Liu","year":"1995","journal-title":"J Pharm Biomed Anal."},{"key":"2021110223543013600_bib10","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10156-012-0368-9","article-title":"Measurement of antifungal drug levels in cerebrospinal fluid for cryptococcal meningoencephalitis","volume":"18","author":"Shoji","year":"2012","journal-title":"J Infect Chemother."},{"key":"2021110223543013600_bib11","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1093\/jac\/dku148","article-title":"Amphotericin B transfer to CSF following intravenous administration of liposomal amphotericin B","volume":"69","author":"Strenger","year":"2014","journal-title":"J Antimicrob Chemother."},{"key":"2021110223543013600_bib12","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s11095-007-9324-2","article-title":"Drug targeting to the brain","volume":"24","author":"Pardridge","year":"2007","journal-title":"Pharm Res."},{"key":"2021110223543013600_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/315643","article-title":"Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system","volume":"182","author":"Groll","year":"2000","journal-title":"J Infect Dis."},{"key":"2021110223543013600_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/j.1439-0507.1997.tb00179.x","article-title":"Comparison of broth macrodilution, broth microdilution and E-test susceptibility tests of Cryptococcus neoformans for fluconazole","volume":"40","author":"Chryssanthou","year":"1997","journal-title":"Mycoses."},{"key":"2021110223543013600_bib15","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1093\/jac\/38.3.485","article-title":"In-vitro and in-vivo evaluation of a new amphotericin B emulsion-based delivery system","volume":"38","author":"Tabosa Do Egito","year":"1996","journal-title":"J Antimicrob Chemother."},{"key":"2021110223543013600_bib16","volume-title":"Cytodiagnostics Introduction to Gold Nanoparticles Characterization","year":"2021"},{"key":"2021110223543013600_bib17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1128\/AAC.33.2.152","article-title":"Effects of free and liposomal amphotericin B and gramicidin S alone and in combination on potassium leakage from human erythrocytes and Candida albicans","volume":"33","author":"Midez","year":"1989","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223543013600_bib18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/QAD.0b013e328322ffac","article-title":"Estimation of the current global burden of cryptococcal meningitis among persons living with HIV\/AIDS","volume":"23","author":"Park","year":"2009","journal-title":"AIDS."},{"key":"2021110223543013600_bib19","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1128\/AAC.38.1.83","article-title":"Effects of antifungal therapy on inflammation, sterilization, and histology in experimental Candida albicans meningitis","volume":"38","author":"Jafari","year":"1994","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223543013600_bib20","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs."},{"key":"2021110223543013600_bib21","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/13693780701730469","article-title":"Renal impairment and amphotericin B formulations in patients with invasive fungal infections","volume":"46","author":"Saliba","year":"2008","journal-title":"Med Mycol."},{"key":"2021110223543013600_bib22","first-page":"5341","article-title":"An optimized nanoparticle delivery system based on chitosan and chondroitin sulfate molecules reduces the toxicity of amphotericin B and is effective in treating tegumentary leishmaniasis","volume":"9","author":"Ribeiro","year":"2014","journal-title":"Int J Nanomed."},{"key":"2021110223543013600_bib23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1186\/s11671-015-0969-1","article-title":"Enhanced Antifungal activity by ab-modified amphotericin B-loaded nanoparticles using a pH-responsive block copolymer","volume":"10","author":"Tang","year":"2015","journal-title":"Nanoscale Res Lett."},{"key":"2021110223543013600_bib24","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2147\/IJN.S17503","article-title":"Efficacy of intravenous amphotericin B-polybutylcyanoacrylate nanoparticles against cryptococcal meningitis in mice","volume":"6","author":"Xu","year":"2011","journal-title":"Int J Nanomedicine."},{"key":"2021110223543013600_bib25","doi-asserted-by":"crossref","first-page":"11873","DOI":"10.1038\/s41598-017-11847-0","article-title":"Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals","volume":"7","author":"Zia","year":"2017","journal-title":"Sci Rep."},{"key":"2021110223543013600_bib26","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1128\/AAC.36.11.2518","article-title":"Effects of aggregation and solvent on the toxicity of amphotericin B to human erythrocytes","volume":"36","author":"Legrand","year":"1992","journal-title":"Antimicrob Agents Chemother."},{"key":"2021110223543013600_bib27","doi-asserted-by":"crossref","first-page":"8662","DOI":"10.1073\/pnas.1307152110","article-title":"Transcytosis and brain uptake of transferrin-containing nanoparticles by tuning avidity to transferrin receptor","volume":"110","author":"Wiley","year":"2013","journal-title":"Proc Natl Acad Sci USA."}],"container-title":["Medical Mycology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/11\/1085\/40811084\/myab042.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/advance-article-pdf\/doi\/10.1093\/mmy\/myab042\/39728821\/myab042.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/mmy\/article-pdf\/59\/11\/1085\/40811084\/myab042.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,2]],"date-time":"2021-11-02T23:54:58Z","timestamp":1635897298000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mmy\/article\/59\/11\/1085\/6333233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,31]]},"references-count":27,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2021,7,31]]},"published-print":{"date-parts":[[2021,11,3]]}},"URL":"https:\/\/doi.org\/10.1093\/mmy\/myab042","relation":{},"ISSN":["1369-3786","1460-2709"],"issn-type":[{"value":"1369-3786","type":"print"},{"value":"1460-2709","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,11]]},"published":{"date-parts":[[2021,7,31]]}}}